Tenax Therapeutics Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
Rhea-AI Summary
Tenax Therapeutics (Nasdaq:TENX) granted non-qualified stock options as Nasdaq Listing Rule 5635(c)(4) inducement awards to three newly hired, non-executive employees in accounting, clinical operations, and CMC/product development roles.
The July 1, 2026 grants cover an aggregate 160,000 shares, with time-based vesting over four years.
Positive
- None.
Negative
- None.
News Market Reaction – TENX
In the Jul 6 session, TENX gained 5.17%, reflecting a notable positive market reaction. Argus tracked a peak move of +9.7% during that session. Our momentum scanner triggered 11 alerts that day, indicating notable trading interest and price volatility.
Data tracked by StockTitan Argus on the day of publication.
Key Figures
Historical Context
| Date | Event | Sentiment | 24h Move | Catalyst |
|---|---|---|---|---|
| May 12 | Earnings and update | Positive | +1.8% | Q1 2026 results, strong cash runway and Phase 3 trial timing update. |
| May 08 | Inducement grants | Neutral | +2.5% | Stock option inducement awards to four newly hired non-executive employees. |
| May 04 | Leadership change | Positive | +4.2% | Appointment of a new Chief Commercial Officer to lead launch preparation. |
| Apr 22 | Leadership change | Positive | -1.5% | Appointment of a new Chief Financial Officer with related inducement awards. |
| Mar 10 | Earnings and update | Positive | +31.7% | FY 2025 results, Phase 3 progress, IP notice, and multi-year cash runway. |
24h Move is the share-price change in the day after each event; other market factors may also have contributed.
Recent corporate and earnings updates have usually seen the shares trade higher, with only one modest downside reaction in the last five reported events.
Key Terms
non-qualified stock options financial
nasdaq listing rule 5635(c)(4) regulatory
AI-generated analysis. How Rhea-AI works. Not financial advice.
CHAPEL HILL, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- Tenax Therapeutics, Inc. (Nasdaq: TENX) (“Tenax” or “Tenax Therapeutics” or the “Company”), a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies, today announced it awarded inducement option awards on July 1, 2026 as material inducements to the employment of three non-executive individuals newly hired by the Company in various accounting, clinical operations, and CMC/product development roles.
The employees received or will receive, in the aggregate, non-qualified stock options to purchase 160,000 shares of the Company's common stock with an exercise price equal to the closing price of the Company's common stock as reported by Nasdaq on the date of grant,
The Awards were each approved by the Board's Compensation Committee, which is comprised solely of independent directors, as material inducements to the employees entering into employment with the Company in accordance with Nasdaq Listing Rule 5635(c)(4) and were granted outside of the Company's stockholder-approved equity incentive plan.
About Tenax Therapeutics
Tenax Therapeutics, Inc. is a Phase 3, development-stage pharmaceutical company using clinical insights to develop novel cardiopulmonary therapies. The Company owns global rights to develop and commercialize levosimendan, including TNX-103 (oral levosimendan) which it is developing for the treatment of PH-HFpEF, the most prevalent form of pulmonary hypertension globally, for which no product has been approved to date. For more information, visit www.tenaxthera.com. Tenax Therapeutics’ common stock is listed on The Nasdaq Stock Market LLC under the symbol “TENX”.
Caution Regarding Forward-Looking Statements
Except for historical information, all of the statements, expectations and assumptions contained in this press release are forward-looking statements. These forward-looking statements may include information concerning possible or projected future business operations. Actual results might differ materially from those explicit or implicit in the forward-looking statements. Important factors that could cause actual results to differ materially include: our ability to maintain our culture and recruit, integrate and retain qualified personnel and advisors, including our executives and on our Board of Directors; risks of our clinical trials, including, but not limited to, the timing, delays, costs, design, location, initiation, enrollment, and results of such trials; any delays in regulatory review and approval of product candidates in development; risks related to our business strategy, including the prioritization and development of product candidates; our estimates regarding the potential market opportunity for our product candidates; reliance on third parties, including Orion Corporation, our manufacturers and CROs; risks regarding the formulation, production, marketing, customer acceptance and clinical utility of our product candidates; the potential advantages of our product candidates; our competitive position; intellectual property risks; volatility and uncertainty in the global economy and financial markets in light of unexpected changes in tariffs and the possibility of pandemics, global financial and geopolitical uncertainties, including in the Middle East and the Russian invasion of and war against the country of Ukraine; risks associated with our cash needs; changes in legal, regulatory and legislative environments in the markets in which we operate, and the impact of these changes on our ability to obtain regulatory approval for our products; and other risks and uncertainties set forth from time to time in our SEC filings. Tenax Therapeutics assumes no obligation and does not intend to update these forward-looking statements except as required by law.
Contacts
Investor and Media:
Argot Partners
tenax@argotpartners.com
